Forte Biosciences Inc (FBRX)
0.745
+0.02
(+2.41%)
USD |
NASDAQ |
May 10, 16:00
0.73
-0.02
(-2.01%)
After-Hours: 20:00
Forte Biosciences Enterprise Value: -10.01M for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | -10.01M |
| May 09, 2024 | -10.65M |
| May 08, 2024 | -9.829M |
| May 07, 2024 | -11.25M |
| May 06, 2024 | -10.92M |
| May 03, 2024 | -11.14M |
| May 02, 2024 | -12.01M |
| May 01, 2024 | -12.70M |
| April 30, 2024 | -10.15M |
| April 29, 2024 | -10.74M |
| April 26, 2024 | -11.06M |
| April 25, 2024 | -10.23M |
| April 24, 2024 | -10.92M |
| April 23, 2024 | -10.24M |
| April 22, 2024 | -10.92M |
| April 19, 2024 | -10.41M |
| April 18, 2024 | -8.737M |
| April 17, 2024 | -10.19M |
| April 16, 2024 | -10.43M |
| April 15, 2024 | -11.28M |
| April 12, 2024 | -10.80M |
| April 11, 2024 | -10.92M |
| April 10, 2024 | -10.56M |
| April 09, 2024 | -10.87M |
| April 08, 2024 | -11.61M |
| Date | Value |
|---|---|
| April 05, 2024 | -11.69M |
| April 04, 2024 | -10.56M |
| April 03, 2024 | -11.83M |
| April 02, 2024 | -11.01M |
| April 01, 2024 | -11.38M |
| March 28, 2024 | -11.79M |
| March 27, 2024 | -11.83M |
| March 26, 2024 | -11.30M |
| March 25, 2024 | -11.28M |
| March 22, 2024 | -11.63M |
| March 21, 2024 | -12.01M |
| March 20, 2024 | -11.67M |
| March 19, 2024 | -13.10M |
| March 18, 2024 | -13.72M |
| March 15, 2024 | -14.56M |
| March 14, 2024 | -13.50M |
| March 13, 2024 | -13.54M |
| March 12, 2024 | -12.67M |
| March 11, 2024 | -11.32M |
| March 08, 2024 | -9.616M |
| March 07, 2024 | -9.168M |
| March 06, 2024 | -10.24M |
| March 05, 2024 | -11.22M |
| March 04, 2024 | -12.05M |
| March 01, 2024 | -10.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-32.37M
Minimum
Nov 15 2023
540.22M
Maximum
Sep 28 2020
104.56M
Average
-11.61M
Median
Apr 08 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 73.41M |
| AIM ImmunoTech Inc | 7.580M |
| IGC Pharma Inc | 31.58M |
| NovaBay Pharmaceuticals Inc | 2.377M |
| Protalix BioTherapeutics Inc | 56.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.872M |
| Total Expenses (Quarterly) | 6.381M |
| EPS Diluted (Quarterly) | -0.04 |
| Earnings Yield | -139.6% |